Olaparib Synergizes with Arsenic Trioxide by Promoting Apoptosis and Ferroptosis in Platinum-resistant Ovarian Cancer

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2022 Sep 26

PMID 36163324

Authors

Sangsang Tang

Yuanming Shen

Xinyi Wei

Zhangjin Shen

Weiguo Lu

Junfen Xu

Affiliations

Soon will be listed here.

Abstract

Poly (ADP-ribose) polymerase (PARP) inhibitors are efficacious in treating platinum-sensitive ovarian cancer (OC), but demonstrate limited efficiency in patients with platinum-resistant OC. Thus, further investigations into combined strategies that enhance the response to PARP inhibitors (PARPi) in platinum-resistant OC are required. The present study aimed to investigate the combined therapy of arsenic trioxide (ATO) with olaparib, a common PARPi, and determine how this synergistic cytotoxicity works in platinum-resistant OC cells. Functional assays demonstrated that the combined treatment of olaparib with ATO significantly suppressed cell proliferation and colony formation, and enhanced DNA damage as well as cell apoptosis in A2780-CIS and SKOV3-CIS cell lines. Results of the present study also demonstrated that a combination of olaparib with ATO increased lipid peroxidation and eventually triggered ferroptosis. Consistently, the combined treatment synergistically suppressed tumor growth in mice xenograft models. Mechanistically, ATO in combination with olaparib activated the AMPK α pathway and suppressed the expression levels of stearoyl-CoA desaturase 1 (SCD1). Collectively, results of the present study demonstrated that treatment with ATO enhanced the effects of olaparib in platinum-resistant OC.

Citing Articles

Olaparib reverses prostate cancer resistance to Rapamycin by promoting macrophage polarization towards the M1 phenotype.

Ye K, Shi G, Xu J, Qiao K, Dai Q, Huo Z Mol Cell Biochem. 2025; .

PMID: 39984794 DOI: 10.1007/s11010-025-05231-0.

Yang Y, Yu S, Liu W, Zhuo Y, Qu C, Zeng Y Cancer Drug Resist. 2025; 8:1.

PMID: 39935430 PMC: 11813627. DOI: 10.20517/cdr.2024.151.

Niraparib restricts intraperitoneal metastases of ovarian cancer by eliciting CD36-dependent ferroptosis.

Jin N, Qian Y, Jiao X, Wang Z, Li X, Pan W Redox Biol. 2025; 80:103528.

PMID: 39922130 PMC: 11851289. DOI: 10.1016/j.redox.2025.103528.

PARylation of HMGA1 desensitizes esophageal squamous cell carcinoma to olaparib.

Lei X, He K, Li Q, Zhang L, Wu D, Yang J Clin Transl Med. 2024; 14(12):e70111.

PMID: 39690136 PMC: 11652107. DOI: 10.1002/ctm2.70111.

Interactions between ferroptosis and tumour development mechanisms: Implications for gynaecological cancer therapy (Review).

Wu P, Chen J, Li H, Lu H, Li Y, Zhang J Oncol Rep. 2024; 53(2).

PMID: 39635847 PMC: 11638741. DOI: 10.3892/or.2024.8851.

References

Wilson M, Pujade-Lauraine E, Aoki D, Mirza M, Lorusso D, Oza A . Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol. 2016; 28(4):727-732. PMC: 6246494. DOI: 10.1093/annonc/mdw663. View

Garrido M, Fredes A, Lobos-Gonzalez L, Valenzuela-Valderrama M, Vera D, Romero C . Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer. Biomedicines. 2022; 10(1). PMC: 8772950. DOI: 10.3390/biomedicines10010077. View

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G . Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016; 17(11):1579-1589. DOI: 10.1016/S1470-2045(16)30376-X. View

Xiao J, Zhang S, Tu B, Jiang X, Cheng S, Tang Q . Arsenite induces ferroptosis in the neuronal cells via activation of ferritinophagy. Food Chem Toxicol. 2021; 151:112114. DOI: 10.1016/j.fct.2021.112114. View

Chan D, Yung M, Chan Y, Xuan Y, Yang H, Xu D . MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis. Pharmacol Res. 2020; 161:105157. DOI: 10.1016/j.phrs.2020.105157. View

Viswanathan V, Ryan M, Dhruv H, Gill S, Eichhoff O, Seashore-Ludlow B . Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017; 547(7664):453-457. PMC: 5667900. DOI: 10.1038/nature23007. View

Wang C, Shi M, Ji J, Cai Q, Zhao Q, Jiang J . Stearoyl-CoA desaturase 1 (SCD1) facilitates the growth and anti-ferroptosis of gastric cancer cells and predicts poor prognosis of gastric cancer. Aging (Albany NY). 2020; 12(15):15374-15391. PMC: 7467382. DOI: 10.18632/aging.103598. View

Lord C, Ashworth A . The DNA damage response and cancer therapy. Nature. 2012; 481(7381):287-94. DOI: 10.1038/nature10760. View

Cha Y, Park D, Lee C, Baek S, Kim S, Kim J . Arsenic trioxide induces apoptosis in human colorectal adenocarcinoma HT-29 cells through ROS. Cancer Res Treat. 2009; 38(1):54-60. PMC: 2741655. DOI: 10.4143/crt.2006.38.1.54. View

10.

Zheng J, Chang K, Jin Y, Zhao X, Li B, Yang M . Arsenic Trioxide Inhibits the Metastasis of Small Cell Lung Cancer by Blocking Calcineurin-Nuclear Factor of Activated T Cells (NFAT) Signaling. Med Sci Monit. 2019; 25:2228-2237. PMC: 6446656. DOI: 10.12659/MSM.913091. View

11.

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B . The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017; 7(3):339-348. PMC: 5651054. DOI: 10.15171/apb.2017.041. View

12.

Xu C, Wang X, Zhou Y, Chen F, Wang H, Li K . Synergy between arsenic trioxide and JQ1 on autophagy in pancreatic cancer. Oncogene. 2019; 38(47):7249-7265. DOI: 10.1038/s41388-019-0930-3. View

13.

Kanakkanthara A, Hou X, Ekstrom T, Zanfagnin V, Huehls A, Kelly R . Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma. Cancer Res. 2021; 82(2):307-319. PMC: 8770599. DOI: 10.1158/0008-5472.CAN-21-0732. View

14.

Tesfay L, Paul B, Konstorum A, Deng Z, Cox A, Lee J . Stearoyl-CoA Desaturase 1 Protects Ovarian Cancer Cells from Ferroptotic Cell Death. Cancer Res. 2019; 79(20):5355-5366. PMC: 6801059. DOI: 10.1158/0008-5472.CAN-19-0369. View

15.

du Bois A, Luck H, Meier W, Adams H, Mobus V, Costa S . A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003; 95(17):1320-9. DOI: 10.1093/jnci/djg036. View

16.

Ascenzi F, De Vitis C, Maugeri-Sacca M, Napoli C, Ciliberto G, Mancini R . SCD1, autophagy and cancer: implications for therapy. J Exp Clin Cancer Res. 2021; 40(1):265. PMC: 8383407. DOI: 10.1186/s13046-021-02067-6. View

17.

Moore K, Secord A, Geller M, Miller D, Cloven N, Fleming G . Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019; 20(5):636-648. DOI: 10.1016/S1470-2045(19)30029-4. View

18.

Swisher E, Kwan T, Oza A, Tinker A, Ray-Coquard I, Oaknin A . Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun. 2021; 12(1):2487. PMC: 8093258. DOI: 10.1038/s41467-021-22582-6. View

19.

Ling S, Xie H, Yang F, Shan Q, Dai H, Zhuo J . Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1. J Hematol Oncol. 2017; 10(1):59. PMC: 5329912. DOI: 10.1186/s13045-017-0424-0. View

20.

Lheureux S, Gourley C, Vergote I, Oza A . Epithelial ovarian cancer. Lancet. 2019; 393(10177):1240-1253. DOI: 10.1016/S0140-6736(18)32552-2. View